Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized diabetes care: study tests if some patients can safely ditch mealtime insulin

NCT ID NCT06148376

Knowledge-focused Sponsor: Hospital Arnau de Vilanova Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a personalized medicine approach in 239 people with type 2 diabetes who use multiple daily insulin injections. Researchers used blood tests (C-peptide and GAD antibodies) to see if some patients could safely stop their mealtime insulin and switch to other diabetes treatments. Participants wore a continuous glucose monitor and were followed for 6 months to check blood sugar control, safety, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
discontinuation of prandial insulin and switch to other diabetes treatments if indicated
What this could lead to
If successful, this could help doctors personalize diabetes care by safely reducing insulin injections for some patients, simplifying their treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may not be definitive. The approach may only work for a subset of patients and requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

239 people

The number who actually took part.

Started

Dec 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All the patients in our territory treated with multiple dose insulin therapy without exclusion criteria are elegible to participate.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Type 2 diabetes treated with multiple dose insulin therapy Exclusion Criteria: * Gestation or planning gestation in the following 12 months * Glucocorticoid use for an acute condition * Transient insulinisationt (less than 6 months) * Any condition that prevents the patient or their caregiver from following up for 6 months * Severe mental illness * Drug or alcohol abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple dose insulin therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple dose insulin therapy Type 2 diabetes mellitus

Contacts and locations

Locations

  • Centres Atenció Primària Lleida, Alt Pirineu i Aran

    Lleida, Spain

  • Hospital Universitari Arnau de Vilanova

    Lleida, 25198, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.